Key result
Ketorolac use in children after congenital cardiac surgery was associated with a 100% rate of platelet inhibition compared to 8.3% in those not receiving ketorolac (P<0.0001).
Why the study?
Does ketorolac cause platelet inhibition in children after congenital cardiac surgery?
Cohort (n=53)
Does ketorolac cause platelet inhibition in children after congenital cardiac surgery?
Absolute Event Rate: 100% vs 8.3%
p-value: p=<.0001
Ketorolac use for analgesia in children after congenital cardiac surgery is associated with significant platelet inhibition via the arachidonic acid pathway.
No takes yet. Share an insight, caveat, or question.
Associated platelet inhibition warrants bleeding caution post-surgery; leaves open randomized confirmation of clinical bleeding risk.
Kim et al. (2018) conducted a cohort in Congenital heart surgery with cardiopulmonary bypass (n=53). Ketorolac vs. No ketorolac was evaluated on Platelet inhibition via the arachidonic acid pathway (p=<.0001). Ketorolac use in children after congenital cardiac surgery was associated with a 100% rate of platelet inhibition compared to 8.3% in those not receiving ketorolac (P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: